专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06548536B2 Agent for inducing apoptosis 失效
标题翻译：诱导细胞凋亡的药物
公开(公告)号：US06548536B2
公开(公告)日：2003-04-15
申请号：US09793654
申请日：2001-02-27
申请人： Mitsunobu Hara , Takayuki Nakashima , Yutaka Kanda , Masami Hamano , Shun-ichi Ikeda , Yuko Uosaki , Yoko Takata , Junji Kanazawa
发明人： Mitsunobu Hara , Takayuki Nakashima , Yutaka Kanda , Masami Hamano , Shun-ichi Ikeda , Yuko Uosaki , Yoko Takata , Junji Kanazawa
IPC分类号： A61K3134
CPC分类号： C07D407/14 , A61K31/00 , A61K31/365 , C07H17/08
摘要： Agents for inducing apoptosis comprising a tetrocarcin derivative represented by the following formula (I) or a salt thereof as an active ingredient (---- represents a single bond or a double bond; j and k represent 0 or 1; R1 to R3, R7 to R10 and R14 represent a hydrogen atom, a lower alkyl group and the like; R4, R11, R12, R13 and R15 to R18 represent a hydrogen atom, a hydroxyl group, a lower alkyl group and the like; R5 and R6 represents a hydrogen atom, a hydroxyl group, a lower alkyl group, a group represented by the following formula (B) (R32 represents a formyl group and the like, R33 to R35 represent a hydrogen atom, a hydroxyl group, a lower alkyl group and the like); R19 represents a hydroxyl group, a lower alkoxyl group, a lower alkanoyloxy group and the like). The agents are useful as medicaments for preventive and/or therapeutic treatment of diseases resulting from increased expression of Bcl-2 family proteins, for example, cancers, AIDS and the like.
摘要翻译：用于诱导凋亡的药剂，其包含由下式（I）表示的四环卟啉衍生物或其盐作为活性成分（----表示单键或双键; j和k表示0或1; R 1至R 3， R 7〜R 10和R 14表示氢原子，低级烷基等; R 4，R 11，R 12，R 13，R 15〜R 18表示氢原子，羟基，低级烷基等; R 5，R 6表示氢原子，羟基，低级烷基，下式（B）表示的基团（R32表示甲酰基等，R33〜R35表示氢原子，羟基，低级烷基，类似）; R 19表示羟基，低级烷氧基，低级烷酰氧基等）。这些药剂可用作预防和/或治疗由Bcl-2家族蛋白（例如癌症，AIDS等）表达增加而引起的疾病的药物。

2. 发明授权

US06495365B1 Hematopoietic stem cell proliferating agents 失效
标题翻译：造血干细胞增殖剂
公开(公告)号：US06495365B1
公开(公告)日：2002-12-17
申请号：US09147689
申请日：1999-05-13
申请人： Yoshimasa Saito , Yoshiko Ueda , Kouichi Tamura , Yoko Takata , Hisashi Yamada , Tatsuo Yamashita , Masakazu Kobayashi
发明人： Yoshimasa Saito , Yoshiko Ueda , Kouichi Tamura , Yoko Takata , Hisashi Yamada , Tatsuo Yamashita , Masakazu Kobayashi
IPC分类号： C12N500
CPC分类号： A61K38/30 , A61K2300/00
摘要： This invention relates to a hematopoietic stem cell proliferating agent comprising IGF-I, a hematopoietic stem cell proliferating agent comprising IGF-I and at least one protein selected from among SCF, M-CSF, and G-CSF, and a method of growing hematopoietic stem cells which comprises culturing hematopoietic stem cells in a medium containing IGF-I and at least one protein selected from the group consisting of SCF and M-CSF. The hematopoietic stem cell proliferating agent of the invention causes hematopoietic stem cells to proliferate in the undifferentiated state whether in vivo or in vitro and can, therefore, be used for amelioration of the cytopenia induced by radiotherapy or chemotherapy using anticancer drugs, prevention of infectious diseases associated with lymphopenia, or in vitro culture for multiplication of hematopoietic stem cells and extrasomatic culture of recombinant stem cells in gene therapy.
摘要翻译：本发明涉及造血干细胞增殖剂，其包含IGF-I，包含IGF-I的造血干细胞增殖剂和选自SCF，M-CSF和G-CSF中的至少一种蛋白质，以及造血造血干细胞增殖的方法干细胞，其包括在含有IGF-I和至少一种选自SCF和M-CSF的蛋白质的培养基中培养造血干细胞。本发明的造血干细胞增殖剂引起造血干细胞在未分化的细胞中增殖说明是否在体内或体外，因此可以用于改善由放射治疗或化疗引起的血细胞减少症，使用抗癌药物，预防与淋巴细胞减少有关的感染性疾病，或体外培养造血干细胞和外植体培养物基因治疗中的重组干细胞。

3. 发明授权

US07037892B2 Hematopoietic stem cell proliferating agents 失效
公开(公告)号：US07037892B2
公开(公告)日：2006-05-02
申请号：US10198355
申请日：2002-07-19
申请人： Yoshimasa Saito , Yoshiko Ueda , Kouichi Tamura , Yoko Takata , Hisashi Yamada , Tatsuo Yamashita , Masakazu Kobayashi
发明人： Yoshimasa Saito , Yoshiko Ueda , Kouichi Tamura , Yoko Takata , Hisashi Yamada , Tatsuo Yamashita , Masakazu Kobayashi
IPC分类号： A61K38/30
CPC分类号： A61K38/30 , A61K2300/00
摘要： This invention relates to a hematopoietic stem cell proliferating agent comprising IGF-I, a hematopoietic stem cell proliferating agent comprising IGF-I and at least one protein selected from among SCF, M-CSF, and G-CSF, and a method of growing hematopoietic stem cells which comprises culturing hematopoietic stem cells in a medium containing IGF-I and at least one protein selected from the group consisting of SCF and M-CSF.The hematopoietic stem cell proliferating agent of the invention causes hematopoietic stem cells to proliferate in the undifferentiated state whether in vivo or in vitro and can, therefore, be used for amelioration of the cytopenia induced by radiotherapy or chemotherapy using anticancer drugs, prevention of infectious diseases associated with lymphopenia, or in vitro culture for multiplication of hematopoietic stem cells and extrasomatic culture of recombinant stem cells in gene therapy.

4. 发明授权

US06825018B1 Sorbitol dehydrogenase, gene encoding the same and use thereof 失效
标题翻译：山梨醇脱氢酶，编码相同的基因及其用途
公开(公告)号：US06825018B1
公开(公告)日：2004-11-30
申请号：US09926163
申请日：2001-12-21
申请人： Takashi Shibata , Chiyo Ichikawa , Mitsutaka Matsuura , Yuji Noguchi , Yoshimasa Saito , Michio Yamashita , Yoko Takata
发明人： Takashi Shibata , Chiyo Ichikawa , Mitsutaka Matsuura , Yuji Noguchi , Yoshimasa Saito , Michio Yamashita , Yoko Takata
IPC分类号： C12N904
CPC分类号： C12N9/0006 , C12P7/60 , C12P19/02
摘要： A gene encoding D-sorbitol dehydrogenase (SLDH); a process for producing SLDH by culturing host cells transformed by an expression vector having the above gene; and a process for processing L-sorbose or 2-keto-L-gulonic acid (2KLGA) by using the above culture. 2KLGA is an important intermediate in the production of L-ascorbic acid. Thus, a process for producing L-ascorbic acid from the 2KLGA obtained by the above process is also provided.
摘要翻译：编码D-山梨醇脱氢酶（SLDH）的基因; 通过培养由具有上述基因的表达载体转化的宿主细胞产生SLDH的方法; 和通过使用上述培养物处理L-山梨糖或2-酮-L-古洛糖酸（2KLGA）的方法。 2KLGA是L-抗坏血酸生产中的重要中间体。因此，还提供了通过上述方法得到的2KLGA生产L-抗坏血酸的方法。

5. 发明申请

US20060135401A1 Novel method of selecting immunosuppressant having little thrombocytopenic effect 审中-公开
标题翻译：选择具有很小血小板减少作用的免疫抑制剂的新方法
公开(公告)号：US20060135401A1
公开(公告)日：2006-06-22
申请号：US10519678
申请日：2003-07-07
申请人： Takao Fujimura , Hiroaki Mori , Katsuhiko Yoshizawa , Yoko Takata , Ichiro Aramori , Hideaki Matsuoka , Akira Unami , Takahisa Noto
发明人： Takao Fujimura , Hiroaki Mori , Katsuhiko Yoshizawa , Yoko Takata , Ichiro Aramori , Hideaki Matsuoka , Akira Unami , Takahisa Noto
IPC分类号： A61K38/17 , G01N33/567
CPC分类号： C12Q1/6897 , C12Q1/6883 , G01N33/5047 , G01N33/6869 , G01N33/6872 , G01N2333/55
摘要： The invention relates to a novel method for selecting an immunosuppressive agent with a less thrombocytopenia effect. According to the invention, a method for selecting an immunosuppressive agent which has a potent immunosuppressive activity but a lower thrombocytopenia effect, said method comprising measuring an IL-2 transcription inhibitory activity in a test cell in to which an IL-2 reporter gene has been introduced in the coexistence of an analyte, while measuring a GATA-1 transcription inhibitory activity in the test cell into which a GATA-1 reporter gene has been introduced in the coexistence of an analyte, and comparing both the transcription inhibitory activities, is provided.
摘要翻译：本发明涉及一种选择血小板减少作用较小的免疫抑制剂的新方法。根据本发明，一种选择具有有效的免疫抑制活性但较低的血小板减少症的免疫抑制剂的方法，所述方法包括测量IL-2转录抑制活性，其中IL-2报告基因已被在分析物共存的同时测量在分析物共存中引入了GATA-1报道基因的测试细胞中的GATA-1转录抑制活性，并比较两种转录抑制活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式